To prospectively evaluate the utility of genomic expression data as a tool to better characterize the tumors of individual patients, and to understand how genomic information from individual patients undergoing routine clinical testing can be used in population-level analysis to improve treatment and outcomes.
Observational study involving the release of tumor genome-wide expression data generated by the Decipher assay which will be linked to clinical treatment and outcome data for patients in whom Decipher clinical testing was performed. The GRID database population will be used to characterize the genomics of cancer and discover or validate gene expression signatures that may be useful for understanding of the biology of the disease and implementing precision medicine approaches for cancer patients.
Study Type
OBSERVATIONAL
Enrollment
1,000,000
The Decipher are gene expression-based tests that are used to better risk stratify or characterize tumor biology that are commercially available through Veracyte, Inc CLIA \& CAP certified laboratory in San Diego, CA
Link complete genomic RNA expression array data generated from Decipher testing with clinical data for patients who consent to participate.
Role of genomic expression data in the biology of certain cancers
Time frame: Through study completion, an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.